PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 90058874 |
---|---|
MARK SECTION | |
MARK | OJJAARA (see, http://uspto.report/TM/90058874/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | OJJAARA |
OWNER SECTION (current) | |
NAME | GLAXOSMITHKLINE LLC |
INTERNAL ADDRESS | 251 LITTLE FALLS DRIVE |
MAILING ADDRESS | CORPORATION SERVICE COMPANY |
CITY | WILMINGTON |
STATE | Delaware |
ZIP/POSTAL CODE | 19808 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
OWNER SECTION (proposed) | |
NAME | GLAXOSMITHKLINE LLC |
INTERNAL ADDRESS | 251 LITTLE FALLS DRIVE |
MAILING ADDRESS | CORPORATION SERVICE COMPANY |
CITY | WILMINGTON |
STATE | Delaware |
ZIP/POSTAL CODE | 19808 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Christopher M. Hanes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Christopher M. Hanes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
DOCKET/REFERENCE NUMBER | 84210939 |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use |
GOODS OR SERVICES | KEEP ALL LISTED |
INTERNATIONAL CLASS | 042 |
CURRENT IDENTIFICATION | Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; scientific research and development; scientific laboratory services; medical laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes |
GOODS OR SERVICES | KEEP ALL LISTED |
INTERNATIONAL CLASS | 044 |
CURRENT IDENTIFICATION | Medical services; medical testing services; DNA screening and analysis services for medical purposes |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 4 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 08/03/2021 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 3 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 375 |
TOTAL AMOUNT | 375 |
SIGNATURE SECTION | |
SIGNATURE | /Christopher M. Hanes/ |
SIGNATORY'S NAME | Christopher M. Hanes |
SIGNATORY'S POSITION | Attorney of record, North Carolina bar member |
DATE SIGNED | 08/01/2023 |
SIGNATORY'S PHONE NUMBER | 9194507041 |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Tue Aug 01 12:23:27 ET 2023 |
TEAS STAMP | USPTO/ESU-XXX.XXX.XXX.XX- 20230801122328344320-9005 8874-85074cd69a95e2b888b5 84a06ade8736ca13fa33993bb c7fabf336e7b5f461977-DA-2 3275305-20230729114319643 480 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |